JP2010538062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538062A5 JP2010538062A5 JP2010523991A JP2010523991A JP2010538062A5 JP 2010538062 A5 JP2010538062 A5 JP 2010538062A5 JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010523991 A JP2010523991 A JP 2010523991A JP 2010538062 A5 JP2010538062 A5 JP 2010538062A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- azithromycin
- release solid
- sustained
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 238000009472 formulation Methods 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims description 42
- 229960004099 azithromycin Drugs 0.000 claims description 42
- 230000009246 food effect Effects 0.000 claims description 12
- 235000021471 food effect Nutrition 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims 57
- 239000012730 sustained-release form Substances 0.000 claims 54
- 238000013268 sustained release Methods 0.000 claims 53
- 238000002360 preparation method Methods 0.000 claims 40
- 238000000034 method Methods 0.000 claims 27
- 235000020925 non fasting Nutrition 0.000 claims 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims 7
- 206010000496 acne Diseases 0.000 claims 7
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 239000002245 particle Substances 0.000 claims 7
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 3
- 239000011230 binding agent Substances 0.000 claims 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 3
- 229960001681 croscarmellose sodium Drugs 0.000 claims 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 3
- 235000019700 dicalcium phosphate Nutrition 0.000 claims 3
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 239000000945 filler Substances 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 229910000831 Steel Inorganic materials 0.000 claims 1
- 229940085314 azithromycin 250 mg Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000012439 solid excipient Substances 0.000 claims 1
- 239000010959 steel Substances 0.000 claims 1
- 238000006677 Appel reaction Methods 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96750407P | 2007-09-05 | 2007-09-05 | |
| US12/002,417 US8124123B2 (en) | 2007-09-05 | 2007-12-17 | Controlled release azithromycin solid dosages forms |
| PCT/US2008/009169 WO2009032037A1 (en) | 2007-09-05 | 2008-07-30 | Controlled release azithromycin solid dosages forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538062A JP2010538062A (ja) | 2010-12-09 |
| JP2010538062A5 true JP2010538062A5 (enExample) | 2011-09-15 |
Family
ID=40407900
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523991A Revoked JP2010538062A (ja) | 2007-09-05 | 2008-07-30 | 徐放性アジスロマイシン固形製剤 |
| JP2010524023A Withdrawn JP2010538066A (ja) | 2007-09-05 | 2008-09-04 | 皮膚疾患治療用アジスロマイシン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524023A Withdrawn JP2010538066A (ja) | 2007-09-05 | 2008-09-04 | 皮膚疾患治療用アジスロマイシン |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8124123B2 (enExample) |
| EP (2) | EP2197420A4 (enExample) |
| JP (2) | JP2010538062A (enExample) |
| KR (2) | KR20100063088A (enExample) |
| CN (2) | CN101861138A (enExample) |
| AR (1) | AR068368A1 (enExample) |
| AU (2) | AU2008295579A1 (enExample) |
| BR (1) | BRPI0816268A2 (enExample) |
| CA (2) | CA2697496A1 (enExample) |
| RU (2) | RU2010109358A (enExample) |
| WO (2) | WO2009032037A1 (enExample) |
| ZA (2) | ZA201001649B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE482695T1 (de) | 2002-12-13 | 2010-10-15 | Durect Corp | Orale darreichungsform mit flüssigen hochviskosen trägersystemen |
| EP2219622A1 (en) | 2007-12-06 | 2010-08-25 | Durect Corporation | Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition |
| US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
| TW201521769A (zh) | 2013-03-15 | 2015-06-16 | Durect Corp | 具有流變改質劑以減少溶解變異性之組成物 |
| SG11201811760VA (en) | 2016-07-06 | 2019-01-30 | Durect Corp | Oral dosage form with drug composition, barrier layer and drug layer |
| IL314380A (en) * | 2016-10-06 | 2024-09-01 | Orbus Therapeutics Inc | Preparations for administration of aflornithine |
| CN109875970B (zh) * | 2019-01-08 | 2021-08-06 | 石家庄四药有限公司 | 阿奇霉素固体制剂及其制备方法 |
| CN113116859B (zh) * | 2021-04-12 | 2022-08-30 | 海南普利制药股份有限公司 | 阿奇霉素丸芯包衣制剂 |
| WO2023283427A2 (en) * | 2021-07-09 | 2023-01-12 | Verdure Biotech, Inc. | Enteric and delayed release formulations of locally bioavailable drugs (lbd) targeting the colon |
| US12605349B2 (en) | 2024-09-05 | 2026-04-21 | Orbus Therapeutics, Inc. | Methods of treating grade 3 astrocytoma |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
| US5605889A (en) * | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
| HUT77530A (hu) * | 1994-05-06 | 1998-05-28 | Pfizer Inc. | Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák |
| US5543417A (en) * | 1994-10-21 | 1996-08-06 | Merck & Co., Inc. | Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents |
| EP0951278A2 (en) * | 1997-01-03 | 1999-10-27 | ELAN CORPORATION, Plc | Sustained release cisapride mini-tablet formulation |
| US6368628B1 (en) * | 2000-05-26 | 2002-04-09 | Pharma Pass Llc | Sustained release pharmaceutical composition free of food effect |
| US7670627B2 (en) * | 2002-12-09 | 2010-03-02 | Salvona Ip Llc | pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients |
| WO2005020993A1 (en) * | 2003-08-29 | 2005-03-10 | Lifecycle Pharma A/S | Modified release compositions comprising tacrolimus |
| US20050239723A1 (en) * | 2004-04-27 | 2005-10-27 | Amin Avinash N | Compositions and methods useful for treatment of acne |
| US20080199527A1 (en) | 2004-12-21 | 2008-08-21 | Pfizer Inc. | Enteric Coated Azithromycin Multiparticulates |
| US20060280789A1 (en) * | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
| ES2545589T3 (es) * | 2005-04-08 | 2015-09-14 | Abbott Laboratories | Formulaciones farmacéuticas orales que comprenden sales de ácido fenofíbrico |
| EP1945227A4 (en) * | 2005-11-09 | 2009-09-30 | Dow Pharmaceutical Sciences | AZITHROMYCIN FOR THE TREATMENT OF GRANULOMATOUS ROSACEA |
| US7704959B2 (en) * | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
-
2007
- 2007-12-17 US US12/002,417 patent/US8124123B2/en not_active Expired - Fee Related
-
2008
- 2008-07-30 KR KR1020107006490A patent/KR20100063088A/ko not_active Withdrawn
- 2008-07-30 AU AU2008295579A patent/AU2008295579A1/en not_active Abandoned
- 2008-07-30 WO PCT/US2008/009169 patent/WO2009032037A1/en not_active Ceased
- 2008-07-30 CN CN200880105792A patent/CN101861138A/zh active Pending
- 2008-07-30 EP EP08780336A patent/EP2197420A4/en not_active Withdrawn
- 2008-07-30 BR BRPI0816268A patent/BRPI0816268A2/pt not_active IP Right Cessation
- 2008-07-30 RU RU2010109358/15A patent/RU2010109358A/ru unknown
- 2008-07-30 CA CA2697496A patent/CA2697496A1/en not_active Abandoned
- 2008-07-30 JP JP2010523991A patent/JP2010538062A/ja not_active Revoked
- 2008-09-04 AR ARP080103847A patent/AR068368A1/es not_active Application Discontinuation
- 2008-09-04 AU AU2008296903A patent/AU2008296903A1/en not_active Abandoned
- 2008-09-04 CA CA2697537A patent/CA2697537A1/en not_active Abandoned
- 2008-09-04 CN CN200880105803A patent/CN101835475A/zh active Pending
- 2008-09-04 WO PCT/US2008/010355 patent/WO2009032268A1/en not_active Ceased
- 2008-09-04 JP JP2010524023A patent/JP2010538066A/ja not_active Withdrawn
- 2008-09-04 EP EP08829925A patent/EP2197453A4/en not_active Withdrawn
- 2008-09-04 KR KR1020107006491A patent/KR20100054842A/ko not_active Withdrawn
- 2008-09-04 RU RU2010109359/15A patent/RU2010109359A/ru not_active Application Discontinuation
-
2010
- 2010-03-08 ZA ZA2010/01649A patent/ZA201001649B/en unknown
- 2010-03-10 ZA ZA2010/01705A patent/ZA201001705B/en unknown
-
2012
- 2012-01-25 US US13/357,722 patent/US20120121702A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010538062A5 (enExample) | ||
| ES2742525T3 (es) | Composiciones de corticosteroides administradas oralmente | |
| JP6105761B2 (ja) | 腸溶性被覆されたマルチ粒子徐放性ペパーミントオイル組成物及び関連方法 | |
| TWI686215B (zh) | 祛鐵斯若(deferasirox)之口服配方 | |
| JP2011513391A (ja) | ミコフェノラートを含有する徐放性医薬組成物およびその方法 | |
| CN102869349A (zh) | 耐酒精的肠溶药物组合物 | |
| KR20130006638A (ko) | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 | |
| AU2013229990B2 (en) | Controlled-release solid dosage forms of mesalamine | |
| JP2007091758A5 (enExample) | ||
| CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
| RU2744576C2 (ru) | Пероральные фармацевтические композиции месалазина | |
| JPH09500910A (ja) | パラセタモール及びドンペリドンのフィルムコーティング錠 | |
| JP2005528430A5 (enExample) | ||
| JP2008519070A5 (enExample) | ||
| CN101686944A (zh) | 熊去氧胆酸的高剂量组合物 | |
| JP2015500853A (ja) | 即時放出マルチユニットペレットシステム | |
| CN101861138A (zh) | 控释的阿奇霉素固体剂型 | |
| CN107205937A (zh) | 包含富马酸二甲酯的药物珠粒制剂 | |
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| CN101932322A (zh) | 用于治疗丙型肝炎病毒感染的包含HMG-CoA还原酶抑制剂和胆汁酸的药物组合物 | |
| CN109152772B (zh) | 烟酰胺的口服药物组合物 | |
| WO2010023690A2 (en) | Prolonged release formulation of amisulpride | |
| JP2008519069A5 (enExample) | ||
| JP2003510347A (ja) | 抗炎症医薬品製剤 | |
| CA3003237A1 (en) | Pharmaceutical compositions of dimethyl fumarate |